Lyell Immunopharma Inc (LYEL)
2.755
-0.02
(-0.54%)
USD |
NASDAQ |
May 28, 16:00
2.755
0.00 (0.00%)
After-Hours: 20:00
Lyell Immunopharma Cash from Financing (Quarterly): 0.027M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.027M |
| December 31, 2023 | 0.759M |
| September 30, 2023 | -0.143M |
| June 30, 2023 | 1.196M |
| March 31, 2023 | -0.069M |
| December 31, 2022 | 0.863M |
| September 30, 2022 | 4.76M |
| June 30, 2022 | 2.457M |
| March 31, 2022 | 2.555M |
| Date | Value |
|---|---|
| December 31, 2021 | 7.399M |
| September 30, 2021 | -0.531M |
| June 30, 2021 | 393.49M |
| March 31, 2021 | 0.884M |
| December 31, 2020 | 0.338M |
| September 30, 2020 | 0.035M |
| June 30, 2020 | -0.002M |
| March 31, 2020 | 476.42M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.531M
Minimum
Sep 2021
476.42M
Maximum
Mar 2020
52.38M
Average
0.863M
Median
Dec 2022
Cash from Financing (Quarterly) Benchmarks
| GlycoMimetics Inc | 0.0049M |
| Candel Therapeutics Inc | -1.255M |
| Eliem Therapeutics Inc | 0.015M |
| Entrada Therapeutics Inc | 0.206M |
| NovaBay Pharmaceuticals Inc | -0.597M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -42.02M |
| Cash from Investing (Quarterly) | 21.99M |
| Free Cash Flow | -160.68M |
| Free Cash Flow Per Share (Quarterly) | -0.1654 |
| Free Cash Flow to Equity (Quarterly) | -42.05M |
| Free Cash Flow Yield | -23.13% |